皮肌炎市場：按類型、治療類型、分銷管道和地區分類

Dermatomyositis Market, By Type, By Treatment Type, By Distribution Channel, By Geography

出版日期: 2026年03月25日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年皮肌炎市值為6.377億美元，預計2033年將達到9.316億美元。預計從2026年到2033年，該市場將以5.5%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	6.377億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	5.50%	2033年市場規模預測：	9.316億美元

皮肌炎是一種罕見的肌肉發炎性疾病。其臨床表現為對稱性近端肌無力、皮疹以及非皮膚症狀，如食道功能障礙和間質性肺病。皮肌炎與惡性腫瘤密切相關，尤其是在成人。皮肌炎是一種系統性疾病，最常涉及皮膚和肌肉，但也可能涉及關節、食道、肺部，極少數情況下涉及心臟。皮肌炎的典型表現為特徵性皮膚觀察和對稱性近端骨骼肌無力。它也可能累及其他器官系統，例如肺部、心血管系統和消化器官系統。多種因素可導致皮肌炎的發生，包括遺傳因素、免疫因素以及感染疾病、藥物和輻射等環境因素。

此外，皮肌炎分為三種：成人皮肌炎、無肌炎性皮肌炎和幼年（兒童）皮肌炎。無肌炎性皮肌炎是指患者僅出現皮膚症狀而無相關肌肉症狀。幼年（兒童）皮肌炎是皮肌炎的早髮型，是一種伴隨血管病變的全身性自體免疫發炎性肌肉疾病。其特徵為近端對稱性肌無力、獨特的皮膚病變及全身性症狀。

市場動態

市場參與企業正致力於開發治療皮肌炎的新治療方法，預計這將推動預測期內的市場成長。例如，2022年5月，臨床階段生物技術公司Kezar Life Sciences, Inc.公佈了其針對皮肌炎（DM）和多發性肌炎（PM）患者的zetomipuzomib（KZR-616）的PRESIDIO II期臨床試驗結果。 PRESIDIO試驗結果顯示，大多數DM和PM患者的總改善評分（TIS）均有顯著的臨床改善。

本次調查的主要特點。

本報告對全球皮肌炎市場進行了詳細分析，預測期（2026-2033 年）內市場規模及複合年成長率（CAGR%），以 2025 年為基準年。
本報告揭示了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本報告根據以下參數對全球皮肌炎市場的主要企業參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和市場策略。
透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過對全球皮肌炎市場進行分析時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 中非
- 北非

第8章：公司簡介

AstraZeneca Plc.
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略
Bristol-Myers Squibb Company
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略
Octapharma AG
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略
Corbus Pharmaceuticals Holdings, Inc.
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略
CSL Limited
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略
Ermium Therapeutics
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略
Kezar Life Sciences Inc.
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略
Mallinckrodt Plc.
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略
Neovacs
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略
Horizon Therapeutics plc.
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略
Pfizer Inc.
- 公司簡介
- 產品系列
- 主要亮點
- 財務業績
- 市場策略

第9章

調查方法
關於我們

簡介目錄

Product Code: CMI5250

Dermatomyositis Market is estimated to be valued at USD 637.7 Mn in 2026 and is expected to reach USD 931.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 637.7 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.50%	2033 Value Projection:	USD 931.6 Mn

Dermatomyositis is a rare condition that causes muscle inflammation. It presents with symmetric proximal muscle weakness, skin rash, and extra macular manifestations such as esophageal dysfunction and interstitial lung disease. Dermatomyositis is strongly associated with malignancy, especially in adults. Dermatomyositis is a systemic disorder that most frequently affects the skin and muscles but may also affect the joints, the esophagus, the lungs, and less commonly, the heart. Dermatomyositis presents with characteristic skin findings and symmetric proximal skeletal muscle weakness. It can also affect other organ systems such as the pulmonary, cardiovascular, and gastrointestinal systems. Various factors cause dermatomyositis such as genetic factors, immunologic factors, and environmental factors such as infections, drugs, and radiation.

Furthermore, there are three types of dermatomyositis namely, Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS). Dermatomyositis Sine Myositis is a term used to describe patients who are present with the dermatological features of dermatomyositis but an absence of associated muscle findings. Juvenile (childhood) dermatomyositis (JDMS) is an early onset form of dermatomyositis (DM), a systemic, autoimmune inflammatory muscle disorder with vasculopathy, characterized by proximal and symmetrical muscle weakness, evocative skin lesions, and systemic manifestations.

Market Dynamics

Market players are involved in the development of novel treatment for dermatomyositis which is expected to propel the market growth over the forecast period. For instance, in May 2022, Kezar Life Sciences, Inc., a clinical-stage biotechnology company, announced result from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM). The results of the PRESIDIO trial showed that most DM and PM patients saw clinically meaningful improvements in total improvement score (TIS).

Key features of the study

This report provides an in-depth analysis of the global dermatomyositis market, market size (USD Mn), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dermatomyositis market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
Key companies covered as a part of this study include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Neovacs, Horizon Therapeutics plc., and Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dermatomyositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis market

Dermatomyositis Market Segmentation

By Type (Revenue, USD Mn, 2020 - 2033)
- Adult Dermatomyositis
- Dermatomyositis Sine Myositis
- Juvenile (Childhood) Dermatomyositis (JDMS)
By Treatment Type Insights (Revenue, USD Mn, 2020 - 2033)
- Anti-inflammatory Medication
- Immunosuppressive Drugs
- Immunoglobulin
- Others (Plasma Exchange, Monoclonal antibody among others)
By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region Insights (Revenue, USD Mn, 2020 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Octapharma AG
- Corbus Pharmaceuticals Holdings, Inc.
- CSL Limited
- Ermium Therapeutics
- Kezar Life Sciences Inc.
- Mallinckrodt Plc.
- Neovacs, Horizon Therapeutics plc.
- Pfizer Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Market Opportunity Map

3. Global Dermatomyositis Market Insights

Drivers
Restraints
Opportunity
Impact Analysis
Pipeline Analysis
PEST Analysis
Porter's Five Forces Analysis
Key Developments
Regulatory Scenario
Reimbursement Scenario
Merger & Acquisition Scenario
Brand Mapping

4. Global Dermatomyositis Market, By Type, 2026 - 2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Adult Dermatomyositis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Dermatomyositis Sine Myositis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Juvenile (Childhood) Dermatomyositis (JDMS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)

5. Global Dermatomyositis Market, By Treatment Type, 2026 - 2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Anti-inflammatory Medication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Immunosuppressive Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Immunoglobulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Others (Plasma Exchange, Monoclonal antibody among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)

6. Global Dermatomyositis Market, By Distribution Channel, 2026 - 2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)

7. Global Dermatomyositis Market, By Region, 2026 - 2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Region at Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country/Region, 2020-2033, (USD Mn)
  - South Africa
  - Central Africa
  - North Africa

8. Company Profiles

AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Octapharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Corbus Pharmaceuticals Holdings, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CSL Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ermium Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Kezar Life Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mallinckrodt Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Neovacs
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Horizon Therapeutics plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies